share_log

8-K: Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance

8-K: Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance

8-K:Biote公布2024年第二季度财务业绩程序收入增长连续加速 BioTerx的推出步入正轨,并计划进一步扩张。管理层重申了2024年的财务指导
美股SEC公告 ·  08/08 16:48
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息